Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study.

Authors:
Zhang H; Tong Z; Liu L; Fu Q; Zhu X and 5 more

Journal:
Gastroenterol Rep (Oxf)

Publication Year: 2023

DOI:
10.1093/gastro/goac088

PMCID:
PMC9897170

PMID:
36751477

Journal Information

Full Title: Gastroenterol Rep (Oxf)

Abbreviation: Gastroenterol Rep (Oxf)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest The authors have no conflicts of interest to declare."

Evidence found in paper:

"Funding This study was supported by National Natural Science Foundation of China (NSFC) [82074208], National Natural Science Foundation of China (NSFC) [81472346] and Natural Science Foundation of Zhejiang Province [LY20H160033]. Clinical trial registration: ClinicalTrials.gov (NCT02558868)."

Evidence found in paper:

"Funding: This study was supported by National Natural Science Foundation of China (NSFC) [82074208], National Natural Science Foundation of China (NSFC) [81472346] and Natural Science Foundation of Zhejiang Province [LY20H160033]. Clinical trial registration: ClinicalTrials.gov (NCT02558868)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025